头颈部鳞状细胞癌患者在根治性放化疗前后的免疫检查点表达。
Immune checkpoint expression in HNSCC patients before and after definitive chemoradiotherapy.
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, Ulm, Germany.
Institute of Pathology, University of Ulm, Ulm, Germany.
出版信息
Head Neck. 2021 Mar;43(3):778-787. doi: 10.1002/hed.26534. Epub 2020 Nov 6.
BACKGROUND
Primary platinum-based chemoradiotherapy (CRT) remains the treatment of choice for nonresectable squamous cell carcinoma of the head and neck (HNSCC). Immune-checkpoint modulators are used as palliative therapy and studied in combination with definitive CRT. However, the immunological changes by CRT need yet to be understood.
METHODS
A cohort consisting of 67 paired tissue biopsies (N = 134) of HNSCC patients before and after CRT was created. The expression of PD-1, PD-L1, and CD27 of tumor and immune cells by immunohistochemistry was evaluated.
RESULTS
PD-L1 expression on immune cells of non-responders was significantly lower before CRT (P = .008). CD27 was expressed only on immune cells and not on cancer cells. A significant lower CD27-expression score was observed following CRT (P = .019).
CONCLUSIONS
Conventional CRT changes the expression of CD27 in the tumor microenvironment. Whether this is due to a loss of expression or a reduction of CD27+ cells must be evaluated in further analyses.
背景
铂类为基础的放化疗（CRT）仍是不可切除的头颈部鳞状细胞癌（HNSCC）的治疗选择。免疫检查点调节剂被用作姑息治疗，并与明确的 CRT 联合研究。然而，CRT 引起的免疫变化仍有待了解。
方法
创建了一个由 67 对接受 CRT 前后的 HNSCC 患者组织活检组成的队列（N = 134）。通过免疫组化评估肿瘤和免疫细胞中 PD-1、PD-L1 和 CD27 的表达。
结果
无应答者的免疫细胞上 PD-L1 的表达在 CRT 前明显较低（P =.008）。CD27 仅在免疫细胞上表达，而不在癌细胞上表达。CRT 后观察到 CD27 表达评分显著降低（P =.019）。
结论
传统 CRT 改变了肿瘤微环境中 CD27 的表达。在进一步的分析中，必须评估这种变化是由于表达丧失还是 CD27+细胞减少所致。
Zotero 插件